The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Survival Benefits of AIDS Treatment in the United States
Abstract
BACKGROUND: As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States. METHODS: We defined eras corresponding to advances in standards of human immunodeficiency virus (HIV) disease care, including opportunistic infection prophylaxis, treatment with ART, and the prevention of mother-to-child transmission (pMTCT) of HIV. Per-person survival benefits for each era were determined using a mathematical simulation model. Published estimates provided the number of adult patients with new diagnoses of AIDS who were receiving care in the United States from 1989 to 2003. RESULTS: Compared with survival associated with untreated HIV disease, per-person survival increased 0.26 years with Pneumocystis jiroveci pneumonia prophylaxis alone. Four eras of increasingly effective ART in addition to prophylaxis resulted in per-person survival increases of 7.81, 11.05, 11.57, and 13.33 years, compared with the absence of treatment. Treatment for patients with AIDS in care in the United States since 1989 yielded a total survival benefit of 2.8 million years. pMTCT averted nearly 2900 infant infections, equivalent to 137,000 additional years of survival benefit. CONCLUSIONS: At least 3.0 million years of life have been saved in the United States as a direct result of care of patients with AIDS, highlighting the significant advances made in HIV disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311801 · Cited by 3,705
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.-Y., Harousseau, J.-L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332305 · Cited by 2,439
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00003 · Cited by 2,067
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C., Hayani, K., Handelsman, E., Smeriglio, V., Hoff, R., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200204150-00009 · Cited by 1,058
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Rosamond, W. D., Chambless, L. E., Folsom, A. R., Cooper, L. S., Conwill, D. E., Clegg, L., Wang, C.-H., & Heiss, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391301 · Cited by 827
Shapiro, M. F., Morton, S. C., McCaffrey, D. F., Senterfitt, J. W., Fleishman, J. A., Perlman, J. F., Athey, L. A., Keesey, J. W., Goldman, D. P., Berry, S. H., et al. (1999) · JAMA · doi:10.1001/jama.281.24.2305 · Cited by 704
Cited by
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
Montaner, J. S., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., Shannon, K., Harrigan, P. R., Hogg, R. S., Daly, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60936-1 · Cited by 780
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627
Retention in Care: A Challenge to Survival with HIV Infection
Giordano, T. P., Gifford, A. L., White, A. C., Almazor, M. E. S., Rabeneck, L., Hartman, C., Backus, L. I., Mole, L. A., & Morgan, R. O. (2007) · Clinical Infectious Diseases · doi:10.1086/516778 · Cited by 566
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 520
Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 499
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P.-M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1909512 · Cited by 487
Redefining the Viral Reservoirs that Prevent HIV-1 Eradication
Eisele, E., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.010 · Cited by 474
Projected life expectancy of people with HIV according to timing of diagnosis
Nakagawa, F., Lodwick, R. K., Smith, C. J., Smith, R., Cambiano, V., Lundgren, J. D., Delpech, V., & Phillips, A. N. (2012) · AIDS · doi:10.1097/qad.0b013e32834dcec9 · Cited by 443
Estimating the Lost Benefits of Antiretroviral Drug Use in South Africa
Chigwedere, P., Seage, G. R., Gruskin, S., Lee, T.-H., & Essex, M. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31818a6cd5 · Cited by 413
Life expectancy living with HIV: recent estimates and future implications
Nakagawa, F., May, M., & Phillips, A. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835ba6b1 · Cited by 373
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, J. V., Peng, G., Rapkin, J., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., Cavert, W. P., Henry, W. K., & Neaton, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb76 · Cited by 372
Eron, J. J., Young, B., Cooper, D. A., Youle, M., DeJesus, E., Andrade-Villanueva, J., Workman, C., Zajdenverg, R., Fätkenheuer, G., Berger, D. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62041-9 · Cited by 317
Lima, V. D., Hogg, R. S., Harrigan, P. R., Moore, D., Yip, B., Wood, E., & Montaner, J. S. (2007) · AIDS · doi:10.1097/qad.0b013e32802ef30c · Cited by 280
Brady, M. T., Oleske, J. M., Williams, P. L., Elgie, C., Mofenson, L. M., Dankner, W. M., & Van Dyke, R. B. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181b9869f · Cited by 278
Chun, T.-W., Justement, J. S., Murray, D., Hallahan, C. W., Maenza, J., Collier, A. C., Sheth, P. M., Kaul, R., Ostrowski, M., Moir, S., et al. (2010) · AIDS · doi:10.1097/qad.0b013e328340a239 · Cited by 276
Masur, H., Brooks, J. T., Benson, C. A., Holmes, K. K., Pau, A. K., & Kaplan, J. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu094 · Cited by 269
Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., Wang, B., Seage III, G. R., Sloan, C. E., Sax, P. E., & Walensky, R. P. (2009) · Clinical Infectious Diseases · doi:10.1086/597095 · Cited by 259
Self-citationEmerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention
Mamo, T., Moseman, E. A., Kolishetti, N., Salvador-Morales, C., Shi, J., Kuritzkes, D. R., Langer, R., Andrian, U. V., & Farokhzad, O. C. (2010) · Nanomedicine · doi:10.2217/nnm.10.1 · Cited by 255
Substance use: impact on adherence and HIV medical treatment
Gonzalez, A., Barinas, J., & O’Cleirigh, C. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0093-5 · Cited by 195
Simoni, J. M., Huh, D., Frick, P. A., Pearson, C. R., Andrasik, M. P., Dunbar, P. J., & Hooton, T. M. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181b9300c · Cited by 174
“0 million years of life in the United States alone.(3) Consistent strict adherence remains key to successful viral suppression.”
BackgroundHIV reservoirs: pathogenesis and obstacles to viral eradication and cure
Chun, T.-W., & Fauci, A. S. (2012) · AIDS · doi:10.1097/qad.0b013e328353f3f1 · Cited by 175
Reddy, K. P., Parker, R. A., Losina, E., Baggett, T. P., Paltiel, A. D., Rigotti, N. A., Weinstein, M. C., Freedberg, K. A., & Walensky, R. P. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw430 · Cited by 135
Self-citationMale Circumcision at Different Ages in Rwanda: A Cost-Effectiveness Study
Binagwaho, A., Pegurri, E., Muita, J., & Bertozzi, S. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000211 · Cited by 114
“For perperson years of survival under treatment we referred to the average life expectancy under care as reported by the US-based Walensky study corresponding to a time in the US before treatment of patients with multidrug resistance was available (and approximating the situation in Rwanda today) [22].”
MethodImpact of cocaine abuse on HIV pathogenesis
Dash, S., Balasubramaniam, M., Villalta, F., Dash, C., & Pandhare, J. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01111 · Cited by 67
Tripathi, A., Liese, A. D., Jerrell, J. M., Zhang, J., Rizvi, A. A., Albrecht, H., & Duffus, W. A. (2014) · Diabetic Medicine · doi:10.1111/dme.12455 · Cited by 74
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket
Waki, K., Durell, S. R., Soheilian, F., Nagashima, K., Butler, S. L., & Freed, E. O. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002997 · Cited by 71
The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis
Passaro, R. C., Pandhare, J., Qian, H.-Z., & Dash, C. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9604-2 · Cited by 66
“The effectiveness of ART has dramatically reduced HIV/AIDS related mortality (Walensky et al. 2006).”
HIV Reservoirs and Treatment Strategies toward Curing HIV Infection
Matsuda, K., & Maeda, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052621 · Cited by 43
Metadata
- Authors
- Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., Weinstein, M. C., & Freedberg, K. A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 194
- Issue
- 1
- Pages
- 11-19
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2136683144
- Cited by
- 581
- References
- 42
- FWCI
- 27.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.